The ALDOB antibody targets aldolase B, a key enzyme encoded by the ALDOB gene, which plays a critical role in fructose metabolism. Aldolase B catalyzes the cleavage of fructose-1-phosphate into dihydroxyacetone phosphate and glyceraldehyde during glycolysis, primarily in the liver, kidneys, and small intestine. Mutations in ALDOB lead to hereditary fructose intolerance (HFI), a rare autosomal recessive disorder characterized by severe metabolic disturbances upon fructose ingestion. ALDOB antibodies are essential tools in research and diagnostics, enabling the detection of aldolase B expression levels in tissues or cell lines. They are widely used in techniques like Western blotting, immunohistochemistry, and ELISA to study enzyme deficiency in HFI patients or explore aldolase B's role in metabolic pathways and diseases, such as cancer or liver dysfunction. Additionally, these antibodies aid in distinguishing ALDOB-related pathologies from other metabolic disorders. Recent studies also investigate aldolase B's potential non-metabolic functions, including interactions with cellular structures or signaling pathways, highlighting its broader biological significance. Commercially available ALDOB antibodies are typically validated for specificity, often generated in animal hosts (e.g., rabbit or mouse) using recombinant protein fragments. Ongoing research continues to refine their applications in both clinical and experimental contexts.